Press Releases

02.28.2018

Inserm announces research agreement with Pfizer Inc. to study rare neuromuscular disease

02.23.2018

Pfizer Receives Positive CHMP Opinion for Two Hematology Medicines, MYLOTARG™ and BOSULIF®

02.23.2018

Pfizer Announces Update on European Marketing Authorization Application for SUTENT® (sunitinib) in Adult Patients at High Risk of Recurrent Renal Cell Carcinoma

02.23.2018

Albert Bourla Elected to Pfizer’s Board of Directors

02.14.2018

Pfizer Receives Breakthrough Therapy Designation from FDA for PF-04965842, an oral JAK1 Inhibitor, for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis

02.12.2018

U.S., EU and Japan Health Authorities Accept Regulatory Submissions for Review of Pfizer’s Third-Generation ALK Inhibitor Lorlatinib

02.05.2018

Phase 3 PROSPER Trial Shows XTANDI® (enzalutamide) Significantly Reduced the Risk of Metastasis or Death by 71 Percent in Men with Non-Metastatic Castration-Resistant Prostate Cancer

01.30.2018

Pfizer Reports Fourth-Quarter and Full-Year 2017 Results

01.24.2018

Pfizer Announces Positive Top-Line Results For Potential Biosimilar To Rituxan®/MabThera®

01.22.2018

MINDIMMUNE THERAPEUTICS TO CONDUCT RESEARCH ON SPECIALIZED IMMUNE CELLS WITH PFIZER INC.

01.19.2018

Survey of Ulcerative Colitis Patients and Gastroenterologists Indicates that Symptoms May Create a New Reality for Patients

01.17.2018

Circle Pharma announces publication in Journal of Medicinal Chemistry of results from collaboration with Pfizer Inc.